|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM127A |
Gene summary for FAM127A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM127A | Gene ID | 8933 |
| Gene name | retrotransposon Gag like 8C | |
| Gene Alias | CXX1 | |
| Cytomap | Xq26.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | A6ZKI3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8933 | FAM127A | LZE4T | Human | Esophagus | ESCC | 9.11e-03 | -2.90e-01 | 0.0811 |
| 8933 | FAM127A | LZE8T | Human | Esophagus | ESCC | 2.75e-02 | -2.90e-01 | 0.067 |
| 8933 | FAM127A | LZE20T | Human | Esophagus | ESCC | 2.28e-02 | -2.90e-01 | 0.0662 |
| 8933 | FAM127A | LZE24T | Human | Esophagus | ESCC | 7.45e-05 | -2.90e-01 | 0.0596 |
| 8933 | FAM127A | P1T-E | Human | Esophagus | ESCC | 8.73e-15 | 1.18e+00 | 0.0875 |
| 8933 | FAM127A | P2T-E | Human | Esophagus | ESCC | 9.84e-49 | 8.66e-01 | 0.1177 |
| 8933 | FAM127A | P4T-E | Human | Esophagus | ESCC | 2.36e-47 | 1.29e+00 | 0.1323 |
| 8933 | FAM127A | P5T-E | Human | Esophagus | ESCC | 7.93e-13 | 4.98e-01 | 0.1327 |
| 8933 | FAM127A | P8T-E | Human | Esophagus | ESCC | 8.24e-45 | 9.08e-01 | 0.0889 |
| 8933 | FAM127A | P9T-E | Human | Esophagus | ESCC | 1.91e-60 | 1.61e+00 | 0.1131 |
| 8933 | FAM127A | P10T-E | Human | Esophagus | ESCC | 3.91e-62 | 1.32e+00 | 0.116 |
| 8933 | FAM127A | P11T-E | Human | Esophagus | ESCC | 3.04e-24 | 1.22e+00 | 0.1426 |
| 8933 | FAM127A | P12T-E | Human | Esophagus | ESCC | 3.68e-57 | 1.41e+00 | 0.1122 |
| 8933 | FAM127A | P15T-E | Human | Esophagus | ESCC | 4.75e-08 | 5.58e-01 | 0.1149 |
| 8933 | FAM127A | P16T-E | Human | Esophagus | ESCC | 3.41e-20 | 1.62e-01 | 0.1153 |
| 8933 | FAM127A | P17T-E | Human | Esophagus | ESCC | 1.81e-07 | 6.91e-01 | 0.1278 |
| 8933 | FAM127A | P19T-E | Human | Esophagus | ESCC | 1.17e-16 | 2.17e+00 | 0.1662 |
| 8933 | FAM127A | P20T-E | Human | Esophagus | ESCC | 4.27e-23 | 7.13e-01 | 0.1124 |
| 8933 | FAM127A | P21T-E | Human | Esophagus | ESCC | 2.28e-48 | 1.26e+00 | 0.1617 |
| 8933 | FAM127A | P22T-E | Human | Esophagus | ESCC | 3.64e-97 | 2.12e+00 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM127A | SNV | Missense_Mutation | novel | c.284N>A | p.Arg95Gln | p.R95Q | A6ZKI3 | protein_coding | tolerated(0.3) | benign(0) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM127A | SNV | Missense_Mutation | c.329N>G | p.Asp110Gly | p.D110G | A6ZKI3 | protein_coding | tolerated_low_confidence(0.05) | possibly_damaging(0.691) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| FAM127A | SNV | Missense_Mutation | c.112N>T | p.Asp38Tyr | p.D38Y | A6ZKI3 | protein_coding | deleterious(0.02) | probably_damaging(0.938) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| FAM127A | SNV | Missense_Mutation | c.124N>A | p.Glu42Lys | p.E42K | A6ZKI3 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM127A | SNV | Missense_Mutation | novel | c.37G>A | p.Ala13Thr | p.A13T | A6ZKI3 | protein_coding | tolerated(0.36) | benign(0.007) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM127A | SNV | Missense_Mutation | novel | c.143N>A | p.Gly48Asp | p.G48D | A6ZKI3 | protein_coding | tolerated(0.19) | benign(0.238) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| FAM127A | SNV | Missense_Mutation | novel | c.181N>A | p.Asp61Asn | p.D61N | A6ZKI3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A2G0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM127A | SNV | Missense_Mutation | rs761975571 | c.274A>G | p.Asn92Asp | p.N92D | A6ZKI3 | protein_coding | tolerated(0.43) | benign(0.033) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| FAM127A | SNV | Missense_Mutation | c.234N>T | p.Gln78His | p.Q78H | A6ZKI3 | protein_coding | deleterious(0.01) | possibly_damaging(0.667) | TCGA-44-A47A-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM127A | SNV | Missense_Mutation | novel | c.110N>A | p.Thr37Asn | p.T37N | A6ZKI3 | protein_coding | tolerated(0.06) | possibly_damaging(0.787) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |